Prognostic significance of left ventricular hypertrophy regression

Advances in Experimental Medicine and Biology

Volumn 432, Issue , 1997, Pages 199-205

  Agabiti Rosei, Enrico ^a   Muiesan, Maria Lorenza ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROCHLOROTHIAZIDE; PLACEBO; RAMIPRIL;

CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; ECHOCARDIOGRAPHY; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEMODYNAMICS; HUMAN; HYPERTENSION; META ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; REMISSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK FACTOR; SYMPATHETIC TONE;

EID: 0031443480     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4615-5385-4_22     Document Type: Conference Paper

References (29)

1. Kannel WB, Gordon T, Offut T. Left ventricular hypertrophy by electrocardiogram. Prevalence, incidence and mortality in the Framingham study. Ann. Int. Med., 71: 89 (1969).
2. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N. Engl. J Med, 322: 1561-1566 (1990).
3. Koren MJ Devereux RB, Casale PN et al. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension Ann Intern Med, 114: 345-352 (1991).
4. Zanchetti A. Goals of antihypertensive treatment: prevention of cardiovascular events and prevention of organ damage. Blood Pressure, 1: 201-211 (1992).
5. Sen S, Tarazi RC. Reversal of myocardial hypertrophy and influence of the adrenergic system. Am J Physiol, 244: H97-H101 (1983).
6. Fouad FM, Nakashima Y, Tarazi RC, Salcedo EE. Reversal of left ventricular hypertrophy in hypertensive patients treated with methyldopa. lack of association to blood pressure control. Am J Cardiol, 49: 759-801 (1982).
7. Drayer JIM, Gardin JM, Weber MA, Aronow WS. Cadiac muscle mass during vasodilation therapy in hypertension. Clin Pharmacol Ther, 33: 727-732 (1983).
8. Agabiti-Rosei E, Muiesan ML, Romanelli G, et al. Reversal of cardiac hypertrophy by long term treatment with calcium antagonists in hypertensive patients. J Cardiovasc Pharmacol, 12(suppl 6): 75-77 (1988).
9. Dahlöf B, Pennert K, Hansson L. Reversal of Left Ventricular Hypertrophy in Hypertensive Patients. A Metaanalysis of 109 Treatment Studies. Am J Hypertens, 5: 95-110 (1992).
10. Cruickshank J.M. Lewis J, Moore V, Dodd A. Reversibility of left ventricular hypertrophy by differing types of antihypertensive therapy. J. Human Hypertens,6: 85-90 (1992).
11. Agabiti-Rosei E, Muiesan ML, Castellano M. Methodology of studies on reversal of left ventricular hypertrophy. High Blood Press, 2 (suppl 1):11-13 (1993).
12. Schmieder AM. Reversal of left ventricular hypertrophy in essential hypertension: a meta-analysis of randomized double blind studies. JAMA, 275: 1507-1513 (1996).
13. Dahlöf B, Hansson L: The influence of antihypertensive therapy on the structural vascular amplifying mechanism in essential hypertension. Different effects of Enalapril and Hydrochlorothiazide. J Hypertens, 10: 1513-1524 (1992).
14. Schulman S, Weiss J Becker L et al. The effects of antihypertensive therapy on left ventricular mass in elderly patients. New Eng J Med, 322, 19; 1350-1356 (1990).
15. Neaton JD, Grimm RH, Prineas RJ, Stamler J, Grandits GA, Emler P, Cutler JA, Flack JM, Schoenberger JA, McDonald R, Lewis CE, Liebson PR, on behalf of Treatment of Mild Hypertension Study Research Group. Treatment of Mild Hypertension Study. Final results. JAMA, 270: 713-724 (1993).
16. Agabiti-Rosei E, Ambrosioni E, DalPalu' C, Muiesan ML, Zanchetti A on behalf of the RACE Study group. Ace-inhibitor ramipril is more effective than β-blocker atenolol in reducing left ventricular mass in hypertension. Results of the RACE (ramipril cardioprotective evaluation) study. J Hypertens, 13: 1325-1335 (1995).
17. Gottdiener JS, Reda DJ, Massie BM, Materson BJ, Williams DW, Anderson RJ, for the VA Cooperative Study group on antihypertensive Agents. Effect of single-drug therapy on reduction of left ventricular mass in mild to moderate hypertension Comparison of six antihypertensive agents. The Departement of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Circulation, 95: 2007-2014 (1997).
18. Trimarco B, De Luca N, Ricciardelli B, Rosiello G, Volpe M, Condorelli G, Lembo G, Condorelli M. Cardiac function in systemic hypertension before and after reversal of left ventricular hypertrophy. Am J Cardiol, 62: 745-750 (1988).
19. Schmieder RE, Messerli FH, Sturgill D, Garavaglia GE, Nunez BD. Cardiac performance after reduction of myocardial hypertrophy. Am J Med, 87: 22-27 (1989).
20. Muiesan ML, Agabiti-Rosei E, Romanelli G, et al. Improved left ventricular systolic and diastolic function after regression of cardiac hypertrophy, treatment withdrawal and revedelopment of hypertension. J. Cardiovasc. Pharmacol, 17: 179s-181s (1991).
21. Agabiti Rosei E, Romanelli G, Muiesan ML et al. Impaired response of the hypertrophied left ventricle to beta adrenergic stimulation in hypertensive patients. Circulation, 70 (Suppl. II): 61 (1984).
22. Grassi G Gianattasio C, Cleroux J, Cuspidi C, Sampieri L, Mancia G Cardiopulmonary reflex before and after regression of left ventricular hypertrophy in essential hypertension. Hypertension, 12: 227-231 (1988).
23. Messerli FH Ventura HO, Elizardi DJ, Dunn FG, Frolich ED. Hypertension and sudden death: disparate effects of calcium entry blocker and diuretic therapy on cardiac disrrhythmias. Arch. Intern. Med, 149: 1263-1267 (1989).
24. Muiesan ML Rizzoni D, Rulli R, Calebich S, Malerba M, Porteri E, Agabiti-Rosei E. Effect of changes in blood pressure and left ventricular mass induced by antihypertensive treatment on ventricular arrhythmias in essential hypertension. J Hypertens, 11 (suppl 5): s300-301 (1993).
25. Magrini F, Reggiani P, Roberts N, Meazza R, Ciulla M, Zanchetti A. Effects of angiotensin blockade on coronary circulation and coronary reserve. Am J Med, 84: 55-60 (1988).
26. Levy D, Salomon M, D'Agostino R, Belanger A, Kannel WB. Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy. Circulation, 90: 1786-93(1994).
27. Koren MJ, Savage DD, Casale PN, Laragh JH, Devereux RB. Changes in left ventricular mass predict risk in essential hypertension. Circulation, 82 (suppl III): III29 (Abstract) (1990).
28. Yurenev AP, Dyakonova HG, Novikov ID, Vitols A, Pahl L, Haynemann G et al. Management of essential hypertension in patients with different degrees of left ventricular hypertrophy multicenter trial Am J Hypertens, 5 (suppl): 182s-189s (1992).
29. Muiesan ML, Salvetti M, Rizzoni D, Castellano M, Donato F, Agabiti-Rosei E. Association of change in LV mass with prognosis during long-term antihypertensive treatment. J Hypertens 13: 1091-1105(1995).